Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

21 May 2015 : Review article  

Pirfenidone and Nintedanib for Idiopathic Pulmonary Fibrosis: A New Drug Therapy

Priyanka WaniE, Mohamed TelebA, Miraie WardiB, Hasan J. SalamehC

DOI: 10.12659/MSRev.894308

Med Sci Rev 2015; 2:41-48


Idiopathic pulmonary fibrosis (IPF) is a chronic debilitating disease with progressive decline in lung function. The incidence of IPF is higher in males, with median survival of 3–5 years after diagnosis. Recent clinical trials have shown success in effective treatment with pirfenidone and nintedanib. The purpose of this article was to review the literature and determine the safety and efficacy of pirfenidone and nintedanib in patients with IPF. Pirfenidone is an oral drug with anti-fibrotic and anti-inflammatory properties. Three published phase III clinical studies have assessed pirfenidone in IPF (CAPACITY 004 and 006), assessed pirfenidone to confirm efficacy and safety in IPF (ASCEND), and a Japanese trials evaluated pirfenidone for mild-to-moderated IPF. The Japanese and ASCEND trials demonstrated that higher doses of pirfenidone decreased the rate of decline of FVC. The CAPACITY 004 and 006 showed that pirfenidone significantly reduced decline in forced vital capacity (FVC) compared with placebo. The efficacy data provided evidence of treatment benefit in patients with IPF. Nintedanib is a tyrosine kinases inhibitor that inhibits the intracellular receptors of angiogenesis, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF). There have been 2 published trials to improve pulmonary fibrosis with BIBF 1120 (TOMORROW), and high dose in Idiopathic Pulmonary Fibrosis patients (INPULSIS) 1 and 2 evaluating nintedanib for IPF. Both studies assessed nintedanib 150 mg twice daily in IPF patients compared to a placebo group, demonstrating that nintedanib is efficacious in reducing the rate of decline of FVC in patients with IPF.

Keywords: Anti-Inflammatory Agents, idiopathic pulmonary fibrosis, Vital Capacity

Add Comment 0 Comments


01 September 2023 : Editorial  

Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.942244

Med Sci Monit 2023; 29:e942244


In Press

28 Sep 2023 : Clinical Research  

Trends in Hospitalization Duration for Rare Diseases: A Retrospective Analysis of Sarcoidosis, Still's Dise...

Med Sci Monit In Press; DOI: 10.12659/MSM.941536  

27 Sep 2023 : Laboratory Research  

Enhanced Proliferation and Adhesion Marker Gene Expression in Fibroblast Cells: Evaluating the Efficacy of ...

Med Sci Monit In Press; DOI: 10.12659/MSM.941641  

26 Sep 2023 : Clinical Research  

Hypothalamic Injury and Clinical Outcomes in Patients with Post-Traumatic Hyponatremia: A Diffusion Tensor ...

Med Sci Monit In Press; DOI: 10.12659/MSM.942397  

26 Sep 2023 : Clinical Research  

Psychometric Properties of the Polish Version of the FACIT-Sp-12: Assessing Spiritual Well-Being Among Pati...

Med Sci Monit In Press; DOI: 10.12659/MSM.941769  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788


30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750